Free Trial
NASDAQ:KTTA

Pasithea Therapeutics (KTTA) Stock Price, News & Analysis

Pasithea Therapeutics logo
$0.74 -0.01 (-1.44%)
Closing price 07/3/2025 03:35 PM Eastern
Extended Trading
$0.74 0.00 (-0.14%)
As of 07/3/2025 04:53 PM Eastern
Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.

About Pasithea Therapeutics Stock (NASDAQ:KTTA)

Key Stats

Today's Range
$0.73
$0.77
50-Day Range
$0.72
$1.69
52-Week Range
$0.70
$7.50
Volume
67,101 shs
Average Volume
2.08 million shs
Market Capitalization
$5.48 million
P/E Ratio
N/A
Dividend Yield
N/A
Price Target
N/A
Consensus Rating
N/A

Company Overview

Pasithea Therapeutics Stock Analysis - MarketRank™

See Top-Rated MarketRank™ Stocks
20th Percentile Overall Score

KTTA MarketRank™: 

Pasithea Therapeutics scored higher than 20% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

  • Consensus Rating

    There is not enough analysis data for Pasithea Therapeutics.

  • Price to Earnings Ratio vs. the Market

    The P/E ratio of Pasithea Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Earnings Ratio vs. Sector

    The P/E ratio of Pasithea Therapeutics is -0.07, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

  • Price to Book Value per Share Ratio

    Pasithea Therapeutics has a P/B Ratio of 0.07. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.

  • Read more about Pasithea Therapeutics' valuation and earnings.
  • Percentage of Shares Shorted

    2.79% of the float of Pasithea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Pasithea Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pasithea Therapeutics has recently decreased by 19.15%, indicating that investor sentiment is improving significantly.
  • Dividend Yield

    Pasithea Therapeutics does not currently pay a dividend.

  • Dividend Growth

    Pasithea Therapeutics does not have a long track record of dividend growth.

  • Percentage of Shares Shorted

    2.79% of the float of Pasithea Therapeutics has been sold short.
  • Short Interest Ratio / Days to Cover

    Pasithea Therapeutics has a short interest ratio ("days to cover") of 0, which is generally considered an acceptable ratio of short interest to trading volume.
  • Change versus previous month

    Short interest in Pasithea Therapeutics has recently decreased by 19.15%, indicating that investor sentiment is improving significantly.
  • Search Interest

    Only 1 people have searched for KTTA on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.
  • MarketBeat Follows

    4 people have added Pasithea Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 100% compared to the previous 30 days.
  • Insider Buying vs. Insider Selling

    In the past three months, Pasithea Therapeutics insiders have sold more of their company's stock than they have bought. Specifically, they have bought $0.00 in company stock and sold $787.00 in company stock.

  • Percentage Held by Insiders

    16.30% of the stock of Pasithea Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.

  • Percentage Held by Institutions

    Only 23.92% of the stock of Pasithea Therapeutics is held by institutions.

  • Read more about Pasithea Therapeutics' insider trading history.
Receive KTTA Stock News and Ratings via Email

Sign-up to receive the latest news and ratings for Pasithea Therapeutics and its competitors with MarketBeat's FREE daily newsletter.

KTTA Stock News Headlines

Is Elon's empire crumbling?
The Tesla Shock Nobody Sees Coming While headlines scream "Tesla is doomed"... Jeff Brown has uncovered a revolutionary AI breakthrough buried inside Tesla's labs. One that is helping AI escape from our computer screens and manifest itself here in the real world all while creating a 25,000% growth market explosion starting as early as July 23rd.
See More Headlines

KTTA Stock Analysis - Frequently Asked Questions

Pasithea Therapeutics' stock was trading at $3.15 at the beginning of the year. Since then, KTTA shares have decreased by 76.6% and is now trading at $0.7370.

Pasithea Therapeutics Corp. (NASDAQ:KTTA) released its quarterly earnings results on Thursday, May, 15th. The company reported ($1.61) EPS for the quarter.

Pasithea Therapeutics shares reverse split before market open on Tuesday, January 2nd 2024.The 1-20 reverse split was announced on Tuesday, January 2nd 2024. The number of shares owned by shareholders was adjusted after the closing bell on Tuesday, January 2nd 2024. An investor that had 100 shares of stock prior to the reverse split would have 5 shares after the split.

Pasithea Therapeutics (KTTA) raised $17 million in an IPO on Wednesday, September 15th 2021. The company issued 2,898,551 shares at a price of $5.00-$7.00 per share.

Shares of KTTA stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Based on aggregate information from My MarketBeat watchlists, some other companies that Pasithea Therapeutics investors own include Biofrontera (BFRI), Meta Platforms (META), Plug Power (PLUG), QuantumScape (QS), Airbnb (ABNB), Advanced Micro Devices (AMD) and Ginkgo Bioworks (DNA).

Company Calendar

Last Earnings
5/15/2025
Today
7/04/2025
Next Earnings (Estimated)
8/12/2025
Fiscal Year End
12/31/2025

Industry, Sector and Symbol

Stock Exchange
NASDAQ
Sector
Medical
Industry
MED - BIOMED/GENE
Sub-Industry
Pharmaceutical Products
Current Symbol
NASDAQ:KTTA
Fax
N/A
Employees
3
Year Founded
N/A

Profitability

Trailing P/E Ratio
N/A
Forward P/E Ratio
N/A
P/E Growth
N/A
Net Income
-$13.90 million
Pretax Margin
N/A

Debt

Sales & Book Value

Annual Sales
N/A
Price / Cash Flow
N/A
Book Value
$10.60 per share
Price / Book
0.07

Miscellaneous

Free Float
6,231,000
Market Cap
$5.48 million
Optionable
Not Optionable
Beta
0.25
These 7 Stocks Will Be Magnificent in 2025 Cover

Discover the next wave of investment opportunities with our report, 7 Stocks That Will Be Magnificent in 2025. Explore companies poised to replicate the growth, innovation, and value creation of the tech giants dominating today's markets.

Get This Free Report

This page (NASDAQ:KTTA) was last updated on 7/5/2025 by MarketBeat.com Staff
From Our Partners